ADHD medications show dosage sweet spots, with little gain above limits

Researchers have identified the best dosage for each ADHD medication using data from thousands of people with the condition. The new study published in The Lancet Psychiatry provides the most comprehensive view of dosage effects for five commonly used medications for ADHD. The study is titled “Pharmacological interventions for ADHD: a systematic review and dose-effect network meta-analysis.”

Why ADHD medication dosage matters

To help patients and clinicians choose the right dosage, the international research team led by Professor Samuele Cortese from the University of Southampton has also developed a free online tool based on the findings.

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental conditions, affecting about 5% of school-age children and 2% to 3% of adults.

Medication is a key part of treatment, and prescriptions have increased substantially in recent years. However, most clinical guidelines provide limited guidance on the most effective dosages.

How the study was conducted

Finding the right dose is important to avoid dosages that are too low to be effective or too high, causing unwanted side effects. To identify this dosage “sweet spot,” the research team analyzed data from 113 clinical trials, including more than 25,000 participants.

They used an advanced method called dose–effects network meta-analysis, which allowed them to estimate how different doses of each medication affect both effectiveness and side effects.

The results show that patterns differ between medications and age groups.

Key findings and clinical implications

Dr. Mikail Nourredine from the University of Lyon, first author of the study, said, “Overall, our findings suggest that clinicians should avoid using doses that are too low to be effective. If symptoms are not well controlled, the dosage may need to be increased.

“We also found no evidence that going beyond the licensed maximum doses improves average effectiveness, and higher doses are usually linked to more side effects. However, our results derive from group averages. Specific individuals with ADHD may benefit from, and tolerate well, unlicensed doses.”

Evidence from other studies shows that a substantial proportion of children and adolescents are prescribed low dosages without appropriate increases. That’s despite timely and adequate dose adjustments being associated with better adherence to treatment.

Professor Cortese, an NIHR Research Professor at the University of Southampton, commented, “Our study and the tool have the potential to support shared decision-making between clinicians, patients, and families when choosing the best dose. It is not only a clinician’s decision—patients and caregivers should be involved.

“The tool helps show what can be expected from each dose so that the patient knows why that particular dose has been chosen. We are continuing research to further personalize these recommendations based on individual patient characteristics.”

Who’s behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries.

Full profile →

Advertisements

Robert Egan

Bachelor’s in mathematical biology, Master’s in creative writing. Well-traveled with unique perspectives on science and language.

Full profile →